person · Reporting owner

Szyper Linda M

Disclosed activity across 2 companies

Tapewire entity: 46304
SEC CIK: 0001739050

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Harmony Biosciences Holdings, Inc.HRMY · Entity 4381	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Harmony Biosciences Holdings, Inc.

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14	Direct	21,872	Reported balance After 2026-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-14 · Grant · Acquired 21,872 · Balance 21,872 F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Neos Therapeutics, Inc.

Report date March 19, 2021 · Filed March 19, 2021

Section 16 reporting ended · disclosed 2021-03-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-03-19 transaction · row 1 1 source row Row 1 · 2021-03-19 · Disposition to issuer · Disposed 23,453 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.40	Direct	Reported balance After 2021-03-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05	Direct	Reported balance After 2021-03-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-19 · Disposition to issuer · Disposed 22,756 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44	Direct	Reported balance After 2021-03-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-19 · Disposition to issuer · Disposed 46,907 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement).

F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.

F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2026 Filed May 18, 2026 16:19 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	21,872	$0.00 Strike: $30.76	$0.00	Disclosure SEC source: 0001739050-26-000001 · form4-05182026_080544.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,872 Underlying: Common Stock · 21,872 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 15, 2025 Filed May 16, 2025 16:03 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	14,522	$0.00 Strike: $34.23	$0.00	Disclosure SEC source: 0001415889-25-013403 · form4-05162025_080514.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,522 Underlying: Common Stock · 14,522 shares Expires 2035-05-15 F1 · derivative.exercise_date: 1. The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 29, 2024 Filed May 31, 2024 08:53 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	6,336	$0.00 Strike: $29.33	$0.00	Disclosure SEC source: 0001415889-24-014965 · form4-05312024_120528.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,336 Underlying: Common Stock · 6,336 shares Expires 2034-05-29 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 25, 2023 Filed May 26, 2023 16:10 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	5,224	$0.00 Strike: $35.99	$0.00	Disclosure SEC source: 0001415889-23-008838 · form4-05262023_040502.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,693 Underlying: Common Stock · 5,224 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 25, 2024 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
May 20, 2022 Filed May 24, 2022 16:18 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	4,742	$0.00 Strike: $41.33	$0.00	Disclosure SEC source: 0001104659-22-064256 · tm2216688-6_4seq1.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,742 Underlying: Common Stock · 4,742 shares Expires 2032-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2023 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document
November 18, 2021 Filed Nov 29, 2021 16:32 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	5,727	$0.00 Strike: $21.82	$0.00	Disclosure SEC source: 0001104659-21-144472 · tm2133953-2_4seq1.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,727 Underlying: Common Stock · 5,727 shares Expires 2031-11-18 F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments beginning on December 18, 2021. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:31 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerStock Option (Right to Buy) · Derivative	46,907	$0.00 Strike: $1.44	$0.00	Disclosure SEC source: 0001104659-21-039223 · tm219870-8_4seq1.xml · derivative · entry 4 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,907 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:31 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerStock Option (Right to Buy) · Derivative	22,756	$0.00 Strike: $6.05	$0.00	Disclosure SEC source: 0001104659-21-039223 · tm219870-8_4seq1.xml · derivative · entry 3 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,756 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:31 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $8.40	$0.00	Disclosure SEC source: 0001104659-21-039223 · tm219870-8_4seq1.xml · derivative · entry 2 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:31 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerCommon Stock	23,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-039223 · tm219870-8_4seq1.xml · nonDerivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3 · shares: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). Read SEC document
June 10, 2020 Filed Jun 11, 2020 20:24 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantCommon Stock	23,453	$0.00	$0.00	Disclosure SEC source: 0001104659-20-072552 · a4.xml · nonDerivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,453 F1 · security: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest on the one-year anniversary of June 10, 2020. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:34 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantStock Option (Right to Buy) · Derivative	46,907	$0.00 Strike: $1.44	$0.00	Disclosure SEC source: 0001104659-19-035986 · a4.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,907 Underlying: Common Stock · 46,907 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which began on June 13, 2019. Read SEC document
July 02, 2018 Filed Jul 3, 2018 16:41 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantStock Option (Right to Buy) · Derivative	22,756	$0.00 Strike: $6.05	$0.00	Disclosure SEC source: 0001104659-18-043861 · a4.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,756 Underlying: Common Stock · 22,756 shares Expires 2028-07-02 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which began on June 20, 2018. Read SEC document
April 27, 2018 Filed May 1, 2018 18:48 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $8.40	$0.00	Disclosure SEC source: 0001104659-18-029451 · a4.xml · derivative · entry 1 Szyper Linda M · CIK 0001739050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-04-27 F1 · derivative.exercise_date: This stock option will vest in equal quarterly installments over a two-year period which begins on April 27, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.